Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Forsteo ® (teriparatide)
Forsteo® (teriparatide): Administration on Alternate Days
Forsteo is not registered for administration on alternate days and this type of dosing is not recommended. Lilly-sponsored clinical trials have only evaluated the efficacy and safety of once-daily administration of teriparatide
When the individual clinical decision was made to start a treatment with teriparatide in a patient, the recommended dose is 20 mcg teriparatide once daily since the summary of product information does not list other doses of teriparatide for particular situations or specific patient populations.1
Posology according to Summary of Product Characteristics
The recommended dose of Forsteo is 20 micrograms administered once daily.1
The maximum total duration of treatment with Forsteo should be 24 months. The 24-month course of Forsteo should not be repeated over a patient’s lifetime.1
Patients should receive supplemental calcium and vitamin D supplements if dietary intake is inadequate.1
Following cessation of Forsteo therapy, patients may be continued on other osteoporosis therapies.1
1. Forsteo [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.
Date of Last Review: February 10, 2020